Efficacy and safety of BLV monotherapy for chronic hepatitis delta: posttreatment results through 48 weeks after the end of treatment from an interim analysis of a randomised Phase 3 study MYR301

被引：0

作者：

Aleman, S. ^{[1
]}

Brunetto, M. ^{[2
,3
]}

Blank, A. ^{[4
]}

Andreone, P. ^{[5
]}

Bogomolov, P. ^{[6
]}

Chulanov, V. ^{[7
]}

Mamonova, N. ^{[8
]}

Geyvandova, N. ^{[9
]}

Morozov, V. ^{[10
]}

Sagalova, O. ^{[11
]}

Stepanova, T. ^{[12
]}

Chee, G. M. ^{[13
]}

Mercier, R. C. ^{[13
]}

Lichtman, A. ^{[13
]}

Manuilov, D. ^{[13
]}

Arterburn, S. ^{[13
]}

Lau, A. H. ^{[13
]}

Osinusi, A. ^{[13
]}

Christian-Cox, Flo. ^{[13
]}

Duff, F. ^{[13
]}

zur Wiesch, J. Schulze ^{[14
]}

Cornberg, M. ^{[15
]}

Zeuzem, S. ^{[16
]}

Wedemeyer, H. ^{[15
]}

Lampertico, P. ^{[17
,18
]}

机构：

[1] Karolinska Inst, Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden

[2] Univ Hosp Pisa, Reference Ctr Tuscany Reg Chron Liver Dis & Canc, Hepatol Unit, Pisa, Italy

[3] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy

[4] Heidelberg Univ, Heidelberg Univ Hosp, Med Fac Heidelberg, Internal Med Dept Clin Pharmacol & Pharmacoepidemi, Heidelberg, Germany

[5] Univ Modena & Reggio Emilia, Baggiovara Hosp, Internal Med, Modena, Italy

[6] MF Vladimirsky Moscow Reg Res & Clin Inst, Moscow, Russia

[7] Sechenov Univ, Moscow, Russia

[8] Minist Hlth Russian Federat, FSBI Natl Res Med Ctr Phthisiopulmonol & Infect Di, Moscow, Russia

[9] Stavropol Reg Hosp, Stavropol, Russia

[10] LLC Med Co Hepatolog, Samara, Russia

[11] South Ural State Med Univ, Chelyabinsk, Russia

[12] LLC Clin Modern Med, Moscow, Russia

[13] Gilead Sci Inc, Foster City, CA USA

[14] Univ Hosp Hamburg Eppendorf, Med Microbiol, Hamburg, Germany

[15] Hannover Med Sch, Clin Gastroenterol Hepatol Infect Dis & Endocrinol, Hannover, Germany

[16] Goethe Univ, Univ Hosp, Dept Nucl Med, Frankfurt, Germany

[17] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy

[18] Univ Milan, CRC A M&A Migliavacca Ctr Liver Dis, Dept Pathophysiol & Transplantat, Milan, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2025年 / 57卷

关键词：

D O I：

10.1016/j.dld.2025.01.109

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P-69

引用

页数：2

共 47 条

[21] Safety, Pharmacokinetics and Anti-Viral Efficacy of Novel Core Protein Allosteric Modifier GLS4 in Patients with Chronic Hepatitis B: Interim Results from a 48 Weeks Phase 2a Study
Zhang, Hong
Zhu, Xiaoxue
Chen, Hong
Li, Xiaojiao
Hu, Yue
Wu, Min
Li, Cuiyun
Luo, Lin
Zhang, Yingjun
Ding, Hua Yan
Niu, Junqi
Liu, Yan
He, Qingwei
Chen, Yunfu
Ren, Qingyun
Gu, Baohua
Jing, Li
HEPATOLOGY, 2018, 68 (06) : 1454A - 1455A
[22] End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection
Etzion, Ohad
Hamid, Saeed Sadiq
Lurie, Yoav
Gane, Edward
Bader, Nimrah
Yardeni, David
Nevo-Shor, A.
Channa, S. M.
Mawani, Minaz
Parkash, Om
Yang, Kyunghee
Longo, Diane
Gish, Robert G.
Glenn, Jeffrey
Apelian, David
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E32 - E32
[23] Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Buti, Maria
Lim, Young-Suk
Chan, Henry Lik Yuen
Agarwal, Kosh
Marcellin, Patrick
Brunetto, Maurizia R.
Chuang, Wan-Long
Janssen, Harry L. A.
Fung, Scott K.
Izumi, Namiki
Jablkowski, Maciej S.
Abdurakhmanov, Dzhamal
Abramov, Frida
Wang, Hongyuan
Botros, Irina
Yee, Leland J.
Mateo, Roberto
Flaherty, John F.
Osinusi, Anu
Pan, Calvin Q.
Shalimar, X.
Seto, Wai-Kay
Gane, Edward J.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (11-12) : 1573 - 1586
[24] A Phase 3 Study Comparing Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Week 48 Efficacy and Safety Results
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, G. Mani
Oberle, Corinna
Huy Trinh
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry L. Y.
SWISS MEDICAL WEEKLY, 2019, : 25S - 25S
[25] A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis - end of study results from the LOWR HDV-3 study
Koh, C.
Surana, P.
Han, T.
Fryzek, N.
Kapuria, D.
Etzion, O.
Takyar, V.
Rotman, Y.
Canales, R.
Dahari, H.
Yurdaydin, C.
Glenn, J.
Heller, T.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S101 - S102
[26] EFFICACY AND SAFETY RESULTS 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) VS CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB)
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey H.
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, Mani
Trinh, Huy N.
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry L.
GASTROENTEROLOGY, 2019, 156 (06) : S1195 - S1195
[27] Efficacy, safety and patient-reported outcomes up to 52 weeks with tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomised, Phase 3 trials
Papp, Kim
Krueger, James
Feldman, Steven
Langley, Richard G. B.
Tori, Hideshi
Tyring, Stephen K.
Tatulych, Svitlana
Gupta, Pankaj
Mebus, Charles
Tan, Huaming
Luo, Yingchun
Mamolo, Carla
Mallbris, Lotus
Wolk, Robert
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S10 - S10
[28] Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First -in -Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks
Mauro, Michael J.
Minami, Yosuke
Rea, Delphine
Hochhaus, Andreas
Lomaia, Elza
Voloshin, Sergey
Turkina, Anna G.
Kim, Dong-Wook
Apperley, Jane F.
Cortes, Jorge E.
Abdo, Andre N. R.
Fogliatto, Laura
Kim, Dennis Dong Hwan
le Coutre, Philipp D.
Saussele, Susanne
Annunziata, Mario
Hughes, Timothy P.
Chaudhri, Naeem A.
Chee, Lynette C. Y.
Garcia Gutierrez, Valentin
Sasaki, Koji
Kapoor, Shruti
Allepuz, Alex
Quenet, Sarah
Bedoucha, Veronique
Boquimpani, Carla
BLOOD, 2021, 138
[29] Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study
Lim, Seng Gee
Pojoga, Cristina
Janssen, Harry
Gusev, Denis
Plesniak, Robert
Tsuji, Keiji
Janczewska, Ewa
Popescu, Corneliu Petru
Andreone, Pietro
Hou, Jinlin
Arbune, Manuela
Gadano, Adrian
Petrova, Diana
Inoue, Jun
Piratvisuth, Teerha
Lim, Young-Suk
Leerapun, Apinya
Atsukawa, Masanori
Jia, Ji-Dong
Labio, Eternity
Cremer, Jennifer
Elston, Robert
Lukic, Tamara
Quinn, Geoff
Kendrick, Stuart
Bharania, Punam
Campbell, Fiona
Paff, Melanie
Theodore, Dickens
JOURNAL OF HEPATOLOGY, 2022, 77 : S880 - S881
[30] Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study
Yuen, Man-Fung
Plesniak, Robert
Lim, Seng Gee
Tsuji, Keiji
Diaconescu, Gheorghe
Gadano, Adrian
Kim, Ju Hyun
Asselah, Tarik
Yim, Hyung Joon
Heo, Jeong
Rizzardini, Giuliano
Janssen, Harry
Popescu, Corneliu Petru
Petrova, Diana
Wong, Alexander
Indriz, Nevin
Pojoga, Cristina
Tanaka, Yasuhito
Gusev, Denis
Janczewska, Ewa
Cremer, Jennifer
Elston, Robert
Lukic, Tamara
Maynard, Lauren
Kendrick, Stuart
Bharania, Punam
Campbell, Fiona
Paff, Melanie
Theodore, Dickens
JOURNAL OF HEPATOLOGY, 2022, 77 : S881 - S882

← 1 2 3 4 5 →